Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: Requirement for comprehensive complement analysis: Comment

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 3, 2015, Pages 485-486

  Cugno, M ^a   Tedeschi, S ^b   Ardissino, G ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A ANTIBODY; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; ECULIZUMAB; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; MONOCLONAL ANTIBODY;

COMPLEMENT ACTIVATION; DRUG MONITORING; HEMOLYTIC UREMIC SYNDROME; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; ANTAGONISTS AND INHIBITORS; ATYPICAL HEMOLYTIC UREMIC SYNDROME; FEMALE; MALE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT C3; COMPLEMENT C5; FEMALE; HUMANS; MALE;

EID: 84923808792     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12764     Document Type: Letter

References (6)

1. Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014; 12: 1440-8.
2. Wehling C, Kirschfink M. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis. J Thromb Haemost 2014; 12: 1437-9.
3. Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014; 124: 1715-26.
4. Volokhina EB, Westra D, van der Velden TJ, van de Kar NC, Mollnes TE, van den Heuvel LP. Complement activation patterns in atypical hemolytic uremic syndrome during acute phase and in remission. Clin Exp Immunol 2014; doi:10.1111/cei.12426.
5. Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 2014; 64: 633-7.
6. Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation 2014; 98: 1205-12.